<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012021</url>
  </required_header>
  <id_info>
    <org_study_id>13646</org_study_id>
    <nct_id>NCT04012021</nct_id>
  </id_info>
  <brief_title>EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI</brief_title>
  <acronym>EXLIPSE</acronym>
  <official_title>EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI - The EXLIPSE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imago 7</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate the correlation between the characteristics detected by the
      7T MRI equipment and the histological composition of native explanted livers (group A), liver
      graft excluded for donation (group B) and surgical specimens of primary pancreatic tumour,
      which underwent pancreaticoduodenectomy (group C).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Three single groups to be included</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the correlation between the characteristics detected by the MRI equipment and the histological composition of ex-vivo specimens from hepatic and pancreatic tissues and lesions</measure>
    <time_frame>3 years</time_frame>
    <description>The creation of a data-bank will increase the knowledge about imaging features able to characterize many diseases affecting the liver, and to evaluate cell changes that occur in pancreatic cancer and the tumour pathways of spreading; moreover it will provide a reference framework to define proper acquisition protocols for future clinical applications.
Such data will also provide imaging biomarkers of malignant cells, and show the morphological changes that occur in neoplastic lesions after systemic or loco-regional therapies.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Liver Steatosis</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>EX-VIVO SPECIMENS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three groups of ex-vivo surgical specimen:
Group A: native livers in transplant recipients Group B: liver grafts excluded for donation Group C: primary pancreatic cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>7T Magnetic Resonance Imaging</intervention_name>
    <description>T1-weighted and T2-weighted sequences
quantitative magnetic resonance imaging approach
proton spectrum analyses</description>
    <arm_group_label>EX-VIVO SPECIMENS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        GROUP A of Native Liver

        Inclusion Criteria:

          -  informed consent

          -  full possession of one's faculties

          -  patients who are going to undergo liver transplantation, independently from previous
             therapy or from the primary disease they are affected by.

        Exclusion Criteria:

          -  patients affected by polycystic liver disease

          -  excluded from liver transplantation.

        GROUP B of Excluded Grafts

        Inclusion Criteria:

        - liver grafts with histologically proven macrovescic steatosis, not fit for
        transplantation

        Exclusion Criteria:

          -  liver grafts histologically proven macrovescic steatosis fit for transplantation

          -  liver grafts not fit for transplantation due to causes other than steatosis

        GROUP C of Focal Pancreatic Lesion

        Inclusion Criteria:

          -  informed consent

          -  full possession of one's faculties

          -  pancreatic lesion assessed by CT examination and histologically proved, which are
             candidates for pancreaticoduodenectomy or total pancreatectomy

        Exclusion Criteria:

        - excluded from surgery due to the severity of their condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Crocetti, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Crocetti, MD,PhD</last_name>
    <phone>+39 050 99</phone>
    <phone_ext>5551</phone_ext>
    <email>laura.crocetti@med.unipi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosa Cervelli, MD</last_name>
    <phone>+39 050 99</phone>
    <phone_ext>5551</phone_ext>
    <email>rosa.cervelli@virgilio.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Crocetti, MD, PhD</last_name>
      <phone>+39 050 99</phone>
      <phone_ext>5551</phone_ext>
      <email>laura.crocetti@med.unipi.it</email>
    </contact>
    <contact_backup>
      <last_name>Rosa Cervelli, MD</last_name>
      <phone>+ 39 050 99</phone>
      <phone_ext>5551</phone_ext>
      <email>rosa.cervelli@virgilio.it</email>
    </contact_backup>
    <investigator>
      <last_name>Davide Caramella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Balducci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Campani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Cacciato Insilla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo De Simone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ugo Boggi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Kraff O, Fischer A, Nagel AM, Mönninghoff C, Ladd ME. MRI at 7 Tesla and above: demonstrated and potential capabilities. J Magn Reson Imaging. 2015 Jan;41(1):13-33. doi: 10.1002/jmri.24573. Epub 2014 Jan 30. Review.</citation>
    <PMID>24478137</PMID>
  </reference>
  <reference>
    <citation>Pohmann R, Speck O, Scheffler K. Signal-to-noise ratio and MR tissue parameters in human brain imaging at 3, 7, and 9.4 tesla using current receive coil arrays. Magn Reson Med. 2016 Feb;75(2):801-9. doi: 10.1002/mrm.25677. Epub 2015 Mar 29.</citation>
    <PMID>25820458</PMID>
  </reference>
  <reference>
    <citation>Stephenson MC, Gunner F, Napolitano A, Greenhaff PL, Macdonald IA, Saeed N, Vennart W, Francis ST, Morris PG. Applications of multi-nuclear magnetic resonance spectroscopy at 7T. World J Radiol. 2011 Apr 28;3(4):105-13. doi: 10.4329/wjr.v3.i4.105.</citation>
    <PMID>21532871</PMID>
  </reference>
  <reference>
    <citation>Terpstra M, Cheong I, Lyu T, Deelchand DK, Emir UE, Bednařík P, Eberly LE, Öz G. Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T. Magn Reson Med. 2016 Oct;76(4):1083-91. doi: 10.1002/mrm.26022. Epub 2015 Oct 26.</citation>
    <PMID>26502373</PMID>
  </reference>
  <reference>
    <citation>Zakhari S. Bermuda Triangle for the liver: alcohol, obesity, and viral hepatitis. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:18-25. doi: 10.1111/jgh.12207. Review.</citation>
    <PMID>23855291</PMID>
  </reference>
  <reference>
    <citation>Meyers RL, Tiao GM, Dunn SP, McGahren ED 3rd, Langham MR Jr; Central Surgical Review Committee, Children's Oncology Group AHEP-0731, Treatment of Children with All Stages Hepatoblastoma. Surgical management of children with locally advanced hepatoblastoma. Cancer. 2012 Aug 15;118(16):4090-1; author reply 4094-5. doi: 10.1002/cncr.26715. Epub 2012 Jul 3.</citation>
    <PMID>22760520</PMID>
  </reference>
  <reference>
    <citation>Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. Liver Transpl. 2010 Aug;16(8):930-42. doi: 10.1002/lt.22106. Review.</citation>
    <PMID>20677284</PMID>
  </reference>
  <reference>
    <citation>Dhir M, Lyden ER, Smith LM, Are C. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. HPB (Oxford). 2012 Sep;14(9):635-45. doi: 10.1111/j.1477-2574.2012.00500.x. Epub 2012 Jun 19. Review.</citation>
    <PMID>22882201</PMID>
  </reference>
  <reference>
    <citation>Lim KB, Schiano TD. Long-term outcome after liver transplantation. Mt Sinai J Med. 2012 Mar-Apr;79(2):169-89. doi: 10.1002/msj.21302. Review.</citation>
    <PMID>22499489</PMID>
  </reference>
  <reference>
    <citation>Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008 Oct;8(10):1982-9. doi: 10.1111/j.1600-6143.2008.02351.x. Epub 2008 Aug 22. Review.</citation>
    <PMID>18727702</PMID>
  </reference>
  <reference>
    <citation>Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002 Oct;8(10):873-83.</citation>
    <PMID>12360427</PMID>
  </reference>
  <reference>
    <citation>Sposito C, Droz Dit Busset M, Citterio D, Bongini M, Mazzaferro V. The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. Rev Endocr Metab Disord. 2017 Dec;18(4):473-483. doi: 10.1007/s11154-017-9439-7. Review.</citation>
    <PMID>29359266</PMID>
  </reference>
  <reference>
    <citation>Nakao A, Harada A, Nonami T, Kaneko T, Takagi H. Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas. 1996 May;12(4):357-61.</citation>
    <PMID>8740402</PMID>
  </reference>
  <reference>
    <citation>Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Müller BM, Bahra M, Neuhaus P, Dietel M, Kristiansen G, Weichert W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer. 2009 Nov 13;9:395. doi: 10.1186/1471-2407-9-395.</citation>
    <PMID>19912635</PMID>
  </reference>
  <reference>
    <citation>Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer. 2009 Dec 26;9:463. doi: 10.1186/1471-2407-9-463.</citation>
    <PMID>20035626</PMID>
  </reference>
  <reference>
    <citation>Shepherd TM, Thelwall PE, Stanisz GJ, Blackband SJ. Aldehyde fixative solutions alter the water relaxation and diffusion properties of nervous tissue. Magn Reson Med. 2009 Jul;62(1):26-34. doi: 10.1002/mrm.21977.</citation>
    <PMID>19353660</PMID>
  </reference>
  <reference>
    <citation>Yong-Hing CJ, Obenaus A, Stryker R, Tong K, Sarty GE. Magnetic resonance imaging and mathematical modeling of progressive formalin fixation of the human brain. Magn Reson Med. 2005 Aug;54(2):324-32.</citation>
    <PMID>16032673</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Laura Crocetti</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>liver</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>steatosis</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>7 tesla</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

